These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 37649234)
1. Unveiling the Influence of Tumor Microenvironment and Spatial Heterogeneity on Temozolomide Resistance in Glioblastoma Using an Advanced Human In Vitro Model of the Blood-Brain Barrier and Glioblastoma. Lam MS; Aw JJ; Tan D; Vijayakumar R; Lim HYG; Yada S; Pang QY; Barker N; Tang C; Ang BT; Sobota RM; Pavesi A Small; 2023 Dec; 19(52):e2302280. PubMed ID: 37649234 [TBL] [Abstract][Full Text] [Related]
2. pH as a potential therapeutic target to improve temozolomide antitumor efficacy : A mechanistic modeling study. Stéphanou A; Ballesta A Pharmacol Res Perspect; 2019 Feb; 7(1):e00454. PubMed ID: 30705757 [TBL] [Abstract][Full Text] [Related]
3. Overcoming the Blood-Brain Tumor Barrier with Docetaxel-Loaded Mesoporous Silica Nanoparticles for Treatment of Temozolomide-Resistant Glioblastoma. Hsu TI; Chen YP; Zhang RL; Chen ZA; Wu CH; Chang WC; Mou CY; Chan HW; Wu SH ACS Appl Mater Interfaces; 2024 May; 16(17):21722-21735. PubMed ID: 38629735 [TBL] [Abstract][Full Text] [Related]
4. PDIA3P1 promotes Temozolomide resistance in glioblastoma by inhibiting C/EBPβ degradation to facilitate proneural-to-mesenchymal transition. Gao Z; Xu J; Fan Y; Qi Y; Wang S; Zhao S; Guo X; Xue H; Deng L; Zhao R; Sun C; Zhang P; Li G J Exp Clin Cancer Res; 2022 Jul; 41(1):223. PubMed ID: 35836243 [TBL] [Abstract][Full Text] [Related]
5. IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma. Guo G; Sun Y; Hong R; Xiong J; Lu Y; Liu Y; Lu J; Zhang Z; Guo C; Nan Y; Huang Q Clin Transl Oncol; 2020 Aug; 22(8):1252-1262. PubMed ID: 31865606 [TBL] [Abstract][Full Text] [Related]
6. PTRF/Cavin-1 enhances chemo-resistance and promotes temozolomide efflux through extracellular vesicles in glioblastoma. Yang E; Wang L; Jin W; Liu X; Wang Q; Wu Y; Tan Y; Wang Y; Cui X; Zhao J; Tong F; Hong B; Xiao M; Liu X; Fang C; Kang C Theranostics; 2022; 12(9):4330-4347. PubMed ID: 35673568 [No Abstract] [Full Text] [Related]
7. TTK Protein Kinase promotes temozolomide resistance through inducing autophagy in glioblastoma. Yu J; Gao G; Wei X; Wang Y BMC Cancer; 2022 Jul; 22(1):786. PubMed ID: 35850753 [TBL] [Abstract][Full Text] [Related]
8. Intranasal Delivery of Temozolomide-Conjugated Gold Nanoparticles Functionalized with Anti-EphA3 for Glioblastoma Targeting. Wang L; Tang S; Yu Y; Lv Y; Wang A; Yan X; Li N; Sha C; Sun K; Li Y Mol Pharm; 2021 Mar; 18(3):915-927. PubMed ID: 33417456 [TBL] [Abstract][Full Text] [Related]
9. Modulating lncRNA SNHG15/CDK6/miR-627 circuit by palbociclib, overcomes temozolomide resistance and reduces M2-polarization of glioma associated microglia in glioblastoma multiforme. Li Z; Zhang J; Zheng H; Li C; Xiong J; Wang W; Bao H; Jin H; Liang P J Exp Clin Cancer Res; 2019 Aug; 38(1):380. PubMed ID: 31462285 [TBL] [Abstract][Full Text] [Related]
10. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway. Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149 [TBL] [Abstract][Full Text] [Related]
11. Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway. Bi Y; Li H; Yi D; Sun Y; Bai Y; Zhong S; Song Y; Zhao G; Chen Y Mol Pharm; 2018 Nov; 15(11):4912-4925. PubMed ID: 30336060 [TBL] [Abstract][Full Text] [Related]
12. Lomustine and nimustine exert efficient antitumor effects against glioblastoma models with acquired temozolomide resistance. Yamamuro S; Takahashi M; Satomi K; Sasaki N; Kobayashi T; Uchida E; Kawauchi D; Nakano T; Fujii T; Narita Y; Kondo A; Wada K; Yoshino A; Ichimura K; Tomiyama A Cancer Sci; 2021 Nov; 112(11):4736-4747. PubMed ID: 34536314 [TBL] [Abstract][Full Text] [Related]
13. A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme. Kim SS; Rait A; Kim E; Pirollo KF; Chang EH Nanomedicine; 2015 Feb; 11(2):301-11. PubMed ID: 25240597 [TBL] [Abstract][Full Text] [Related]
14. Nano-Codelivery of Temozolomide and siPD-L1 to Reprogram the Drug-Resistant and Immunosuppressive Microenvironment in Orthotopic Glioblastoma. Liu D; Cheng Y; Qiao S; Liu M; Ji Q; Zhang BL; Mei QB; Zhou S ACS Nano; 2022 May; 16(5):7409-7427. PubMed ID: 35549164 [TBL] [Abstract][Full Text] [Related]
15. Exosomal transfer of miR-1238 contributes to temozolomide-resistance in glioblastoma. Yin J; Zeng A; Zhang Z; Shi Z; Yan W; You Y EBioMedicine; 2019 Apr; 42():238-251. PubMed ID: 30917935 [TBL] [Abstract][Full Text] [Related]
16. Propofol enhances the sensitivity of glioblastoma cells to temozolomide by inhibiting macrophage activation in tumor microenvironment to down-regulate HIF-1α expression. Zhao W; Yun K Exp Cell Res; 2022 Sep; 418(2):113277. PubMed ID: 35810776 [TBL] [Abstract][Full Text] [Related]
17. Downregulation of SNRPG induces cell cycle arrest and sensitizes human glioblastoma cells to temozolomide by targeting Myc through a p53-dependent signaling pathway. Lan Y; Lou J; Hu J; Yu Z; Lyu W; Zhang B Cancer Biol Med; 2020 Feb; 17(1):112-131. PubMed ID: 32296580 [No Abstract] [Full Text] [Related]
18. Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma. Zeng A; Wei Z; Yan W; Yin J; Huang X; Zhou X; Li R; Shen F; Wu W; Wang X; You Y Cancer Lett; 2018 Nov; 436():10-21. PubMed ID: 30102952 [TBL] [Abstract][Full Text] [Related]
19. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma. Chen Z; Wei X; Shen L; Zhu H; Zheng X Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207 [TBL] [Abstract][Full Text] [Related]
20. Repurposing an Antiepileptic Drug for the Treatment of Glioblastoma. Yadav A; Alnakhli A; Vemana HP; Bhutkar S; Muth A; Dukhande VV Pharm Res; 2022 Nov; 39(11):2871-2883. PubMed ID: 36195821 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]